Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
about
Morphological changes of glutamatergic synapses in animal models of Parkinson's diseaseAldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's diseaseThe benefits of humanized yeast models to study Parkinson's diseaseUpstream deregulation of calcium signaling in Parkinson's diseaseDNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.Physiological characterisation of human iPS-derived dopaminergic neuronsConverging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's diseaseGDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson diseaseQuantification of mitochondrial morphology in neurites of dopaminergic neurons using multiple parametersAldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulationIonic currents influencing spontaneous firing and pacemaker frequency in dopamine neurons of the ventrolateral periaqueductal gray and dorsal raphe nucleus (vlPAG/DRN): A voltage-clamp and computational modelling study.VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2.Defining a role for hemoglobin in Parkinson's diseaseSoluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction.Nicotinamide nucleotide transhydrogenase (Nnt) links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin (Trx/Prx) system.Chronic behavioral and cognitive deficits in a rat survival model of paraoxon toxicityDifferential neuroprotective and anti-inflammatory effects of L-type voltage dependent calcium channel and ryanodine receptor antagonists in the substantia nigra and locus coeruleusParkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degenerationInvolvement of Mu Opioid Receptor Signaling in the Protective Effect of Opioid against 6-Hydroxydopamine-Induced SH-SY5Y Human Neuroblastoma Cells Apoptosis.Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.Similar molecular determinants on Rem mediate two distinct modes of inhibition of CaV1.2 channels.Circadian dysfunction in response to in vivo treatment with the mitochondrial toxin 3-nitropropionic acid.Polyphenols: multipotent therapeutic agents in neurodegenerative diseases.Neuronal calcium signaling: function and dysfunction.Calcium signaling in Parkinson's disease.Interactions between calcium and alpha-synuclein in neurodegeneration.Vitamin D: a custodian of cell signalling stability in health and disease.Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease.Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions.PKA Phosphorylation of NCLX Reverses Mitochondrial Calcium Overload and Depolarization, Promoting Survival of PINK1-Deficient Dopaminergic NeuronsParkinson's Disease and Neurodegeneration: GABA-Collapse HypothesisCalcium and Parkinson's disease.Cav1.2 and Cav1.3 L-type calcium channels operate in a similar voltage range but show different coupling to Ca(2+)-dependent conductances in hippocampal neurons.The role of Ca2+ signaling in Parkinson's disease.The Hyperpolarization-Activated Current Determines Synaptic Excitability, Calcium Activity and Specific Viability of Substantia Nigra Dopaminergic Neurons.Live calcium and mitochondrial imaging in the enteric nervous system of Parkinson patients and controls.Human umbilical cord mesenchymal stem cells infected with adenovirus expressing HGF promote regeneration of damaged neuron cells in a Parkinson's disease model.Calcium currents regulate dopamine autoreceptors.Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neuronsPINK1-mediated phosphorylation of LETM1 regulates mitochondrial calcium transport and protects neurons against mitochondrial stress.
P2860
Q26781619-336A149D-9E35-4686-A07D-407E2EB482A0Q26850502-FF8889DD-5771-4951-BA2B-835A06D6D54DQ26853041-E84A00C7-E333-4B88-8FB2-F9F76323F6C9Q27026384-F84B9C29-4BCA-49DA-997C-EA9263D0F3AFQ27312297-3EFB3B98-B532-4AAA-AEF7-FF4084C10FE0Q27324718-A6D01B57-C591-4F8F-97F9-8C39C92D9147Q28074143-D8610E07-F38C-4F41-B0E2-E106B2B07322Q28083626-26C7EE35-ECB6-41BA-88DB-F2A73C567AC4Q28272173-CC056F72-97F3-45A4-BA99-CB6772079238Q30581658-9463501D-8EDA-47FD-B1E3-7AFA216DFDE0Q30846890-4895EA35-F407-4678-AC3C-E92CD0A976D1Q33815889-D55BDDE4-3881-42D5-83BC-1966A7E803D7Q33917264-D99F8947-F083-443B-A2F2-A29EE07F78C3Q33985326-19CE8EBA-4280-4677-AB52-CCCDACE0818DQ34075997-D58B3195-E245-41DE-BCE9-A4C8C7DD89E0Q34243561-AE5D4835-45CE-4431-B412-0CDB5982D7DEQ35108124-EDAAB668-057D-40B4-B723-ED33DE0C6366Q36179023-EB211821-D518-4C47-B315-0D2CE1CE9378Q36310081-88649409-259A-46F0-BEB9-03A382B9F6D4Q36372732-6522BE0C-7AF2-4F8D-ADE6-382DEB27FB05Q37183263-6C899075-52ED-41CF-A002-C6633ED9F320Q37476957-3114023C-82C7-4E5B-A511-7FB1C87C1FA3Q38120532-8AD0CDB2-37D8-40E2-BE14-9CB33BF4C7DAQ38179996-ADF2C5F2-8192-480C-91E8-DED36522C7E7Q38208179-69E5FDF5-F03C-4C61-91E3-4D4114F0C053Q38254376-9A2600BE-12E3-4C6E-A1A7-BC6E4DE84A49Q38502035-3FA088C6-B45C-482A-A321-BA26D228797CQ38502057-E1D46023-866B-42F5-9C41-A9E479FCC25BQ38610367-BD01C562-A962-4A5C-B23C-04346E3C2F4AQ38829987-8FA05ABF-D9A7-4D55-B5A4-0F6A807984DAQ38845589-B276933F-251A-4720-89DF-0BEA3FB06D48Q38945252-1747B568-F851-4054-B4BA-E6ABDC0F6B72Q39204655-0F7EEC41-F870-45E1-942B-FFEEACF116EAQ39281423-2EF043E7-91F8-479B-BE70-68DE93C418D4Q41025017-33C2BE1C-E712-4ED2-9057-47029B756A83Q41476211-3CABC2D1-DC3D-4009-9547-4BFE25331EB3Q41718628-DF029E30-7329-4D7B-A5BB-2C5DB3D39F84Q42249313-6BE9D858-C987-4A49-B5EB-0B9DD0F9BE26Q42705179-DE402E8D-427D-4208-A517-A87F89D8A13BQ44168907-9A2D6E02-5E5A-4ED4-AF7C-FA0F8E8BFCD9
P2860
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@ast
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@en
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@nl
type
label
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@ast
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@en
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@nl
prefLabel
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@ast
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@en
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@nl
P2860
P3181
P356
P1476
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
@en
P2093
D. J. Surmeier
P. T. Schumacker
P2860
P304
P3181
P356
10.1074/JBC.R112.410530
P407
P577
2013-04-12T00:00:00Z